Erasca, Tango Therapeutics Launch Phase 1/2 Trial of Cancer Drug Combination

Bitget2026/11/04 13:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Erasca and Tango Therapeutics opened enrollment in a Phase 1/2 trial combining vopimetostat with ERAS-0015 under their collaboration.
The trial targets MTAP-deleted pancreatic cancer and RAS-mutant, MTAP-deleted non-small cell lung cancer.
Tango sponsors the study, whose dose-escalation phase aims to determine the combination’s maximum tolerated dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040830PRIMZONEFULLFEED9870072) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Erasca, Tango Therapeutics Launch Phase 1/2 Trial of Cancer Drug Combination

You may also like

Crypto prices